首页> 外文期刊>Mutation Research, C. Mutation Research Letters >MUTAGENICITY OF NITROBENZYL DERIVATIVES - POTENTIAL BIOREDUCTIVE ANTICANCER AGENTS
【24h】

MUTAGENICITY OF NITROBENZYL DERIVATIVES - POTENTIAL BIOREDUCTIVE ANTICANCER AGENTS

机译:硝基苯衍生物的致突变性-潜在的生物还原抗癌剂

获取原文
获取原文并翻译 | 示例
           

摘要

Ortho-, meta- and para-nitrobenzyl bromides, alcohols, ethers and esters were synthesised and tested for their mutagenicity toward Salmonella typhimurium TA100, TA100NR (nitroreductase deficient) and TA98 in absence of S9 mix and in TA100 with S9 mix. Compounds of the ortho- and meta-series were non mutagenic with and without S9 mix. Except for the alcohol and ether, the compounds of the pam-series were mutagenic in TA100 with activity sequence propionate > butyrate > benzoate > acetate > bromide and this specific activity was reduced considerably by S9 mix. The Ames Salmonella test system does not seem to be an appropriate model to evaluate mutagenicity of o-nitrobenzyls. However, further work is in progress to test all the compounds fbr mutagenicity in mammalian system.
机译:合成了邻,间和对硝基苄基溴,醇,醚和酯,并测试了在没有S9混合物的情况下以及在具有S9混合物的TA100中对鼠伤寒沙门氏菌TA100,TA100NR(缺乏硝基还原酶)和TA98的致突变性。在有和没有S9混合的情况下,邻位和间位系列化合物均不致突变。除醇和醚外,pam系列化合物在TA100中具有致突变性,活性顺序为丙酸酯>丁酸酯>苯甲酸酯>乙酸酯>溴化物,并且通过S9混合大大降低了比活性。 Ames沙门氏菌测试系统似乎不是评估邻硝基苄基致突变性的合适模型。但是,正在进行进一步的工作以测试所有化合物在哺乳动物系统中的致突变性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号